# Uterine leiomyosarcoma – right on time Leiomiossarcoma uterino – na hora certa

Carlos Macedo,¹ Rita Leiria Gomes,¹ Filipa Abreu Santos,¹ Hugo Gaspar,¹ Manuel Pontes¹ Hospital Dr. Nélio Mendonça – SESARAM EPERAM

# **Abstract**

Uterine leiomyosarcomas, although rare, are the most frequent histological type of uterine sarcomas, and have a poor prognosis even when diagnosed in early stages. More often they present with abnormal uterine bleeding, pelvic mass and/or pelvic pain, making the differential diagnosis with uterine leiomyomas. Due to its rarity and aggressiveness, there is no consensus regarding the treatment algorithm. We describe the case of a woman who presented a spontaneous rupture of leiomyosarcoma, a rare manifestation with few cases described in the literature.

**Keywords:** Leiomyosarcoma; Uterine Haemorrhage; Uterine Rupture; Hemoperitoneum.

# Resumo

Os leiomiossarcomas uterinos, embora raros, são o tipo histológico mais frequente de sarcomas uterinos, associados a um mau prognóstico mesmo quando diagnosticados em estadios iniciais. Mais frequentemente apresentam-se com hemorragia uterino anómala, massa pélvica e/ou dor pélvica, fazendo o diagnóstico diferencial com leiomiomas uterinos. Devido à sua raridade e agressividade, não há consenso quanto ao algoritmo de tratamento. Descrevemos o caso de uma mulher com uma rotura espontânea do leiomiossarcoma, uma manifestação rara com poucos casos descritos na literatura.

Palavras-chave: Leiomiossarcoma; Hemorragia uterina anómala; Ruptura uterina; Hemoperitoneu.

## **INTRODUCTION**

U terine sarcomas, are neoplasms of the mesenchymal tissue, correspond to 3 to 7% of uterine tumours and about 1% of neoplasms of the female genital tract. Due to their rarity and histological diversity, it is difficult to classify them, identify risk and prognostic factors, and to define a treatment 1,2,3,4. Leiomyosarcomas correspond to the most frequent histological type (63%), and are associated with a high recurrence rate (53 to 71%), even when diagnosed in early stages². Treatment with tamoxifen is pointed out as a possible

risk factor, although in many cases none risk factor is identified<sup>1,2</sup>.

Abnormal uterine bleeding, a palpable pelvic mass and/or pelvic pain are the most frequent clinical presentations and these can also be manifested in uterine leiomyomas, masking the diagnosis<sup>1,2,5</sup>. For this reason it is important to exclude the presence of a leiomyosarcoma when studying a polymyomatous uterus, especially if we are in the presence of a uterine tumour that grows after menopause<sup>2</sup>. Less often, they present with other manifestations, including hemoperitoneum (due to spontaneous rupture of the tumour), with only a few cases described in the literature<sup>5,6,7,8,9,10</sup>. The authors describe a case of a uterine leiomyosarcoma, with spontaneous rupture.

<sup>1.</sup> Serviço de Ginecologia e Obstetrícia – Hospital Dr. Nélio Mendonça, Funchal, Ilha da Madeira, Portugal.

## **CLINICAL CASE**

We present the case of a 50-year-old Caucasian woman admitted for elective surgery due to a rapidly growing uterine leiomyoma. From her background, she was a nulliparous woman, with non-medicated dyslipidaemia and a BMI of 19. She had no previous surgeries or smoking habits. Regarding family history, she has two paternal female cousins with breast carcinoma. In the history of the current disease, the patient mentioned irregular menstrual cycles with 5 months of evolution, which led her to go to the gynaecology emergency department for an abnormal uterine bleeding one and a half month before surgery. In this episode, a transvaginal ultrasound examination identified a polymyomatous uterus (the largest leiomyoma with 60\*60 mm) and mild anaemia (Haemoglobin 10.5 g/dl), and she was medicated with desogestrel and oral iron. One week after going to the emergency department, the patient scheduled a private gynaecology appointment. In the office evaluation, the aforementioned leiomyoma had 77\*86\*96 mm in dimensions, a FIGO classification type 1-6, vascularization score 2 (Figure 1), but the patient didn't present the previous examination and a subsequent reassessment was scheduled. A month later, due to maintaining the abnormal vaginal bleeding, she contacted her assistant gynaecologist who, upon reassessing, found an increase in the dimensions of the uterine mass, being urgently referred to the gynaecology oncology department and, after discussion in a multidisciplinary team, surgery was scheduled to the following week.

During the surgery, an enlarged uterus was observed with the presence of clots on the uterine fundus, adherence of small bowel loops to the left and adhesions of the sigmoid colon to the left uterine horn. After lysis of the adhesions, a rupture of the lesion was seen (occurred preoperatively), with the presence of coagulated content and material suggestive of myometrial tissue released in the pelvic cavity (Figure 2). Regarding the adnexa, the left ovary was atrophic and with adhesions to the colon, and the fimbriae of the right tube adhered to the ipsilateral utero-ovarian ligament, without other alterations. Surgery proceeded systematically with total hysterectomy and bilateral adnexectomy. After the closure of the vaginal vault, general surgery support was requested to evaluate the intesti-



**FIGURE 1.** Ultrassound images of the tumour, with dimensions of 77\*86\*96 milimiters, and vascularization.

nal segments. Segmental resection of the small intestine was performed with a 55 GIA (5-6 centimetres from the proximal ileum) with latero-lateral mechanical anastomosis. Then an evaluation of the sigmoid colon was carried out, due to the presence of inflammatory/tumoral tissue involving some of the epiploic appendix but without direct invasion of the intestinal wall, it was decided to excise this tissue and send it for anatomopathological examination. All pieces were sent for anatomopathological study. After extensive cleaning of the cavity and review of the haemostasis, a drain was



FIGURE 2. Uterine leiomyosarcoma, with rupture features.

placed in the right iliac fossa and the abdominal wall was closed in layers.

In the postoperative period, when questioned, the patient reported a sudden and intense pain about an hour before surgery, requiring analgesia, which probably corresponded to the moment of rupture. Hospitalization was uneventful, with discharge on the sixth postoperative day, medicated with low molecular weight heparin for thromboprophylaxis, oral iron and painkillers.

The anatomopathological study of the uterus identified 3 nodules. The largest, with dimensions of 6.5\*6 cm, in the microscopic study showed a fusocellular neoplasm with moderate atypia, multifocal areas of marked atypia, necrosis and a mitotic index greater than 10 per 10 fields of high magnification, characteristics suggestive of uterine leiomyosarcoma, with serosa involvement. Regarding the immunocytochemical study: CD 10 negative; CD34 negative; Caldesmon Positive; Desmin Positive; HMB45 Negative; Oestrogen receptors positive; Progesterone receptors positive; and SMA positive. The left utero-ovarian ligament, the serosa of the sigmoid colon and the biopsy of the pelvic peritoneum showed involvement by the previously described neoplasm. Regarding the pathological staging, it was a pT3a tumour (8th edition AJCC) and a FIGO IIIA staging.

Two weeks after the surgery, in a multidisciplinary team appointment, given the anatomopathological result and the imaging study showing signs of tumoral lesion in the splenic angle of the colon and implants at the pelvic level, the patient was proposed for a new surgery. Thus, four weeks after the initial surgery, the patient underwent on an exploratory laparoscopy, which was converted into laparotomy after evaluation of the cavity and possibility of excision of lesions, followed by a left hemicolectomy, with high anterior resection of the rectum, enterectomy, omentectomy, peritoneal biopsies and excision of a node in the vaginal vault. The anatomopathological study showed, in the left hemicolectomy specimen, anterior resection of the rectum and enterectomy, several nodules with signs of leiomyosarcoma, the largest with 15 mm.

In a new multidisciplinary team appointment, it was decided to start chemotherapy (gemcitabine and docetaxel). After 14 months since the first surgery, the patient presents clinical and imaging progression of the disease, maintaining cycles of chemotherapy, with different combinations of drugs through this time.

#### **DISCUSSION**

Uterine leiomyosarcomas are rare and aggressive neoplasms<sup>5,7,9,11</sup>. Prognosis is based on FIGO staging for this type of tumour, mitotic count and tumour size<sup>10</sup>. The five-year survival rate in leiomyosarcomas varies between 15-25%, being associated with a high risk of recurrence and metastasis, with hematogenous dissemination being the main route<sup>2,3,4</sup>.

When a uterine mass is suspected, the first-line study should be a transvaginal ultrasound with Doppler evaluation, which can be complemented with a pelvic magnetic resonance<sup>1</sup>. However, the diagnosis is histological. The mitotic index is an important parameter to establish the diagnosis and prognosis<sup>1,2,10,12</sup>.

As mentioned, uterine tumours most often present with abnormal uterine bleeding, a rapidly growing mass or compressive symptoms, spontaneous rupture is an atypical and rare presentation<sup>1,8,9,10</sup>. In the literature only a few cases of uterine sarcomas with hemoperitoneum as an initial finding, due to tumour rupture, are described<sup>5,6,7,8,9,10</sup>. A possible mechanism

described for this rupture is the degenerative changes, tissue infarction and tumor necrosis<sup>7,13,14</sup>. In the present case, the rupture occurred in the hospital shortly before surgery, hence the initial finding was not a hemoperitoneum. This presentation, being atypical, cannot be used as a prognostic marker<sup>9</sup>.

The treatment of these tumours is surgical and they are usually associated with a poor prognosis, especially if there is tumour dissemination in the pelvic cavity<sup>1,7,15</sup>. Hysterectomy with or without adnexal preservation in early cases has good results in the survival of these patients<sup>1,4,15</sup>. The role of chemotherapy and its possible benefit in leiomyosarcomas isn't fully established, but since they are tumours with a poor prognosis, it is often associated in their treatment, either for therapeutic or palliative effects<sup>3,4,15</sup>. Adjuvant pelvic radiotherapy and pelvic lymphadenectomy showed no effect on survival and are not indicated<sup>4</sup>. Therefore, palliative care should be called early, especially if disseminated disease is present<sup>15</sup>.

Uterine leiomyosarcomas present a clinical challenge, either for being infrequent, for their aggressiveness, and because there is no consensual therapeutic algorithm, so a multidisciplinary approach should be mandatory. This atypical manifestation, although rare, should be taken into account in women with hemoperitoneum and suspected uterine mass.

# REFERENCES

- 1. Wen KC, Horng HC, Wang PH, Chen YJ, Yen MS, Ng HT, et al. Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review. Taiwan J Obstet Gynecol. 2016; 55(4):463-71.
- 2. Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143 Suppl 2:51-8.
- 3. Ginecologia SPd, editor. Cancro Ginecológico Consensos Nacionais 2020. https://spginecologia.pt/academia/consensos/2020.
- 4. Kyriazoglou A, Liontos M, Ntanasis-Stathopoulos I, Gavriatopoulou M. The systemic treatment of uterine leiomyosarcomas: A systematic review. No news is good news? Medicine (Baltimore). 2021;100(13):e25309.
- 5. Özcan J, Dülger Ö, Küpelio lu L, Gönenç A, Er ahin A. Uterine sarcoma in a 14 year-old girl presenting with uterine rupture. Gynecol Oncol Rep. 2014;10:44-6.
- 6. Farhi J, Dicker D, Ben-Rafael Z. Leiomyosarcoma presenting as spontaneous hemoperitoneum. Int J Gynaecol Obstet. 1993;40(3):249-50.

- 7. Boussouni K, Benoulaid M, Dafiri R. [Spontaneous uterine rupture due to uterine leiomyosarcomal. Pan Afr Med J. 2016;24:86.
- 8. Oda H, Hirakawa H. Spontaneous rupture of uterine smooth muscle tumour presenting acute abdominal pain and haemoperitoneum. BMJ Case Rep. 2018;2018.
- 9. Elbiss HM, Neale E. Uterine leiomyosarcoma mimicking a ruptured aortic aneurysm. J Obstet Gynaecol. 2006;26(1):85-6.
- 10. Pulcinelli FM, Catalano A, Malle G, Mossa B, Caserta D. A uterus soaked in blood with low haemoglobin in a case of unrecognized uterine sarcoma. Eur J Gynaecol Oncol. 2016;37(1):122-5.
- 11. Hicks G, McCallum IJ, Ogah K, Guirguis M, Kasaraneni R. Spontaneous uterine perforation secondary to uterine leiomyosarcoma presenting as acute abdomen with haemoperitoneum. J Obstet Gynaecol. 2010;30(2):211-2.
- 12. Conklin CM, Longacre TA. Endometrial stromal tumors: the new WHO classification. Adv Anat Pathol. 2014;21(6):383-93.
- 13. Barua R, Olesnicky G. Uterine leiomyosarcoma presenting with haemoperitoneum. Med J Aust. 1988;148(12):655, 7.
- 14. Gupta N, Dadhwal V, Misra R, Mittal S, Kiran S. Atypical presentation of a leiomyoma as spontaneous massive haemoperitoneum. Eur J Obstet Gynecol Reprod Biol. 2008;138(1):120-1.
- 15. Allanson ER, Cummings M, Kuchel A, Wastney T, Nicklin J. Undifferentiated uterine sarcoma: a multidisciplinary challenge. Int J Gynecol Cancer. 2022;32(2):198-202.

## **AUTHORS' CONTRIBUTIONS**

Carlos Macedo: Conceptualization, Writing – original draft, Writing – review & editing

Rita Leiria Gomes: Writing – review & editing

Filipa Abreu Santos: Conceptualization, Writing – review & editing, Resources

ing, resources

Hugo Gaspar: Writing – review & editing, Resources Manuel Pontes: Writing – review & editing, Resources

# **CONFLICTS OF INTEREST**

Authors declare they have no conflicts of interest.

## **INFORMED CONSENT**

The patient gave informed consent for publication.

#### **CORRESPONDENCE TO:**

Carlos Filipe Coelho da Silva Macedo

Hospital Dr. Nélio Mendonça, Avenida Luís de Camões, n.º 57 – 9004-514 Funchal, Portugal

E-mail: carlosfilmacedo@gmail.com

https://orcid.org/0000-0003-3952-383X

**RECEIVED:** 03/08/2022 **ACCEPTED:** 10/12/2022